



Cite this: *Org. Biomol. Chem.*, 2021, **19**, 233

One pot synthesis of *thio*-glycosides via aziridine opening reactions†

Nives Hribernik,  Alice Tamburrini, Ermelinda Falletta and Anna Bernardi *

A one-pot aziridine opening reaction by glycosyl thiols generated *in situ* from the corresponding anomeric *thio*-acetates affords *thio*-glycosides with a pseudo-disaccharide structure and an *N*-linked tether. The scope of the one-pot aziridine opening reaction was explored on a series of mono- and disaccharides, creating a class of pseudo-glycosidic compounds with potential for further functionalization. Unexpected anomerization of glycosyl thiols was observed under the reaction conditions and the influence of temperature, base and solvent on the isomerization was investigated. Single isomers were obtained in good to acceptable yields for mannose, rhamnose and sialic acid derivatives. The class of *thio*-glycomimetics synthesized can potentially be recognized by various lectins, while presenting hydrolytic and enzymatic stability. The nitrogen functionality incorporated in the glycomimetics can be exploited for further functionalization, including tethering to linkers, scaffolds or peptide residues.

Received 23rd September 2020,
Accepted 12th November 2020

DOI: 10.1039/d0ob01956a

rsc.li/obc

Introduction

It is well known that interactions between carbohydrates and proteins play an important role in physiological and pathological processes of major relevance and yet the therapeutic use of carbohydrates is limited by their difficult synthesis, their low intrinsic activity and their chemical nature, which does not fit expectations for drug-like molecules.¹ To overcome at least some of these drawbacks, chemically modified analogues of natural carbohydrates, so called glycomimetics, have been proposed.² The development of functional carbohydrate mimics has been tackled either by structure-based design,^{1,3–13} or by discovery campaigns, often planned taking advantage of microarray technology.^{14–16} The latter approach has been frustrated by the cumbersome synthesis of oligosaccharides, that severely limits the diversity and the number of compounds that can be rapidly generated.

We have recently reported that the one-pot opening reaction of epoxide **2** by the glycosyl thiol generated *in situ* from 2,3,4,6-tetra-*O*-acetyl-1-*S*-acetyl- α -D-mannopyranose **1** provides a facile access to the 1,2-dimannoside mimic **3**, which is produced as a single isomer resulting from exclusive *trans*-diaxial opening of the epoxide (Scheme 1).¹⁷ The pseudo-*thio*-1,2-dimannoside **3** binds to the dendritic cell receptor DC-SIGN with an affinity comparable to that of the natural disaccharide Man α (1,2)Man,

but is significantly more stable to enzymatic hydrolysis¹⁸ and arguably simpler to synthesize.

Inspired by the potential of this system, we aimed at developing a one-pot procedure for opening the corresponding aziridine **4**. This approach would afford *N*-linked-pseudo-*thio*-disaccharides such as **5**. Natural *N*-linked glycans, which represent one of the most common covalent modification of proteins,¹⁹ are generally connected to an Asn side-chain through a β -GlcNAc residue. Thus, here we are not trying to reproduce or mimic the structure of these glycans, but are using a totally artificial structure (an α -Man mimic) to allow the rapid generation of hydrolytically stable pseudo-glycoconjugates that can be tested in a variety of fashions against relevant carbohydrate binding proteins in drug discovery programs. Initially, we developed the approach using the mannosyl *thio*-acetate **1** as the model compound. We then further explored the scope of the one-pot aziridine opening reaction on various mono- and disaccharides, to create a class of glycomimetics (*N*-linked-pseudo-*thio*-disaccharides) with improved stability and the potential of being recognized by various lectins. While looking into the reaction scope, we observed interesting phenomena connected to the configurational stability of anomeric thiols, some of which unexpectedly underwent anomeric isomerization under the aziridine opening conditions. Our results are reported below.

Results


Synthesis of peracetylated glycosyl *thio*-acetates

Various methods for the synthesis of peracetylated glycosyl *thio*-acetates have been reported. To simplify the synthesis

Università degli Studi di Milano, Dipartimento di Chimica, via Golgi 19, 20133 Milano, Italy. E-mail: anna.bernardi@unimi.it

†Electronic supplementary information (ESI) available. See DOI: 10.1039/d0ob01956a





Scheme 1 One-pot synthesis of the pseudo-*thio*-1,2-dimannoside **3** by epoxide opening (from ref. 17) and the planned approach to the aziridine-opening process (this article).

and at the same time achieve satisfying yields, we selected one-pot procedures with conditions tailored for each sugar individually. The conditions used are summarized in Scheme 2 and described in detail in the ESI.† Briefly, the 1-*S*-acetyl derivatives of mannose (Man), rhamnose (Rha), glucose (Glc), galactose (Gal) and lactose (Lac) (Scheme 2, **1** and **6–9**) were obtained by acid catalysed acetylation of the free sugar, followed by reaction with thioacetic acid (AcSH) under TMSOTf or BF_3 catalysis (two step, one pot).^{20,21} The 1-*S*-acetyl derivatives of sialic acid (Neu5Ac) and *N*-acetylglucosamine (GlcNAc)²² (Scheme 2, **10–11**) were synthesized by reaction of AcSK with the corresponding peracetylated anomeric chloride, generated *in situ* by reaction of the free sugar with AcCl. In most cases, the peracetylated glycosyl *thio*-acetates were obtained as single isomers and, when not, the two isomers were chromatographically separated (see ESI†).

Synthesis of aziridine **4**

The required aziridine **4** was prepared as a single enantiomer by *N*-H aziridination of (1*S*,2*S*)-1,2-dicarboxymethoxy-4-cyclohexene **12**²³ using the method recently introduced by Falck and co-workers.²⁴ The resulting *N*-H aziridine **13** can then be transformed in a variety of amides and carbamates of general formula **4** (Scheme 3). Falck's *N*-H aziridination occurs *via* homogenous Rhodium catalysis ($\text{Rh}_2(\text{esp})_2$, Du Bois' catalyst **14**) and uses *O*-(2,4-dinitrophenyl)hydroxylamine (DPH **15**) as the aminating agent, with no external oxidants. The reaction is operationally simple, fast and scalable, but careful optimization of the reaction conditions was required to avoid dimerization of **13**, a process which occurs rapidly at room temperature to afford **16** (Scheme 3). Under optimal conditions (6 h at 0 °C, addition of 10% catalyst and DPH after 3 h) on a 1.0 mmol scale no dimer was observed and the reaction yield was 90%, after Boc-protection of **13** to afford **4a** (Scheme 3). Boc protection was performed using di-*t*-butyl-dicarbonate and adapting the conditions reported by Mordini and co-workers for a similar substrate.²⁵

Acylation of the aziridine nitrogen protects the molecule against polymerization, while preserving its reactivity as an electrophile in a nucleophilic substitution reaction. The nitrogen protecting group can serve multiple purposes in the design of the glycomimetic structures of our interest, thus a


series of different acylating agents and conditions were explored (Scheme 3). Reaction of **13** with acyl chlorides and pyridine did not afford the expected amide. Rather, products resulting from nucleophilic opening of the aziridine by chloride ions were identified by MS analysis of the crude reaction mixtures.^{26–28} Clean amide formation could be obtained either by carbodiimide-promoted coupling, or using activated esters. The reaction occurred smoothly, including with functionalized and hindered acyl donors **17–20** (Scheme 3), that could be used to install appropriate linkers for further (pseudo)-glyco-conjugation of the fully-formed mimics.

One-pot aziridine opening

The aglycone moiety **4** used in this study was carefully selected for its symmetry properties and high conformational stability, both imparted by the 1,2-*trans*-dicarboxy substituents.²⁹ Additionally, aziridines **4** lack potential chelating groups that have been shown to impinge on the regio- and stereocontrol of nucleophilic substitutions of both cyclitol epoxides and aziridines.^{30,31} Thus we expected a single reaction product to be formed by *trans*-diaxial opening of the aziridine, in keeping with the results of the analogous reaction of epoxide **2** with 1-*S*-acetyl- α -D-mannopyranose **1**.¹⁷

Indeed, reaction of **1** with **4a** (Scheme 4) proceeded smoothly under the conditions established for epoxide **2** (1.9 mol equiv. of Et_2NH in DMF at room temperature). Product **5a** was obtained in 82% yield as a single isomer from a completely selective *trans*-diaxial opening process, preserving, as expected, the α -configuration of mannose. The product configuration was fully confirmed by coupling constant analysis and NOESY, as previously described for **3**.¹⁷ To further explore the role of the nitrogen protecting group in this reaction, substrates **4b–d** were also examined (Scheme 4). Reaction of **1** with **4b** failed to afford the desired aziridine opening product (**5b**), rather the thiolate anion generated *in situ* from **1** displaced the terminal chloride of the linker, to give **21**.³² Steric hindrance of the primary chloride, as in **4c**, abolished this side reaction, and restored the aziridine opening pathway giving **5c** in almost quantitative yields. Reaction of the corresponding azide-bearing compound **4d** was more sluggish, but microwave irradiation of the reaction mixture at 60 °C for 2 h afforded **5d** in 68% yield. The same product was obtained in 71% yield from **5a** by Boc removal





Scheme 2 Synthesis of peracetylated glycosyl thio-acetates **1** and **6–11**.


(TFA, quant) followed by acylation of crude **22** with the *p*-nitrophenyl ester **20**, thus establishing **5a** as an appropriate intermediate for later stage elaboration of the scaffold linker (Scheme 4).

We then moved on to investigate the scope of the aziridine opening approach using the mono- and disaccharide anomeric thio-acetates **6–11** and the *N*-Boc-aziridine **4a** as the model substrate (Scheme 5). The reactions were performed under the conditions established with mannose and their course was followed by LC-MS and/or ^1H NMR. LC-MS revealed that the expected products were formed in most cases within 1 h at room temperature. The main by-product observed was the glycosyl disulphide, as exemplified by **29** for the *gluco* series (Scheme 6). Reaction of **4a** with the α -Rha derivative **6** (Scheme 5) under the conditions established for mannose

afforded **23** with 92% isolated yield (0.3 mmol scale, Table 2, entry 2) as a single α isomer, as established by NOESY experiments (see ESI†).

In the same conditions, however, reaction of the β -Glc thioacetate **7** afforded both the β - and α -isomers **β -24** and **α -24** (Scheme 6) in 2 : 1 ratio, as estimated by integration of the anomeric proton signals at 4.72 and 5.73 ppm, respectively. The two isomers were separated chromatographically ($i\text{Pr}_2\text{O}$: EtOAc eluent), and analysis of coupling constants supported by NOESY-NMR and MS data undoubtedly confirmed their structure and anomeric configuration. Similarly, the disulphide by-product **29** was obtained as an anomeric mixture (see ESI†). This was rather unexpected, because most literature claims configurational stability of glycosyl thiols, particularly under basic conditions.^{33–35}






Scheme 3 Synthesis and acylation of the N-H aziridine **13**, to afford the N-acyl aziridines **4a–d**.

Further experimentation with **7** was based on an analysis of the putative reaction mechanism depicted in Scheme 6: nucleophilic attack of Et₂NH on the thioester generates Et₂NAC and the free thiol **30**, in equilibrium with the thiolate β-**31** under the basic reaction conditions. The thiolate can either attack the aziridine, in an S_N2-like process, or equilibrate, presumably *via* ring-opening (mutarotation conditions) to α-**31**. Additionally, both β and α thiol/thiolate can dimerize to the disulphide, which was found as an anomeric mixture in the reaction crude. Thus, we examined the role of reaction temperature, substrate

concentration, base concentration and solvent on the relative rate of these reactions. The amount of anomeric isomerization strongly depended on temperature: at 0 °C (Table 1, entry 3) the ratio changed to 10 : 1 in favour of the β product β-**24**, but the overall yield of **24** decreased. Reducing the amount of base and/or the substrate concentration did not have an effect on the β : α ratio, but also slowed down the S_N2 reaction process, thus increasing the amount of disulphide by-product (*e.g.* compare entries 1 and 2, 3 and 4, 3 and 5). Changing the solvent from DMF to CH₂Cl₂ (entry 6) gave low yields (16%) of almost pure





Scheme 4 Opening reaction of aziridines **4a–d** with 1-S-acetyl- α -D-mannopyranose **1**. The azide-bearing product **5d** can also be obtained upon acylation of **22** deriving from the *N*-Boc opening product **5a**.


β -product, but dimerization of the glycosyl thiol was the major result. Using both acetonitrile or DMF/CH₂Cl₂ mixtures of various composition (from 7/3 to 9/1) the reaction was slow and low yields of β : α = 3 : 1 were obtained (not shown in the table). Thus, it appears that low temperatures (0 °C) favour aziridine opening over anomerization. A high concentration of substrate is also beneficial, by increasing the rate of the nucleophilic substitution. A solvent of lower polarity as CH₂Cl₂ appears to reduce anomeric isomerization, but it also slows down the S_N2 reaction, thus resulting in low yields and extensive dimerization of the thiol. Reducing the amount of base has no influence on the selectivity, but again favors dimerization over the formation of the aziridine opening product **24**.

As an alternative, the one-pot aziridine procedure could be split in two consecutive reactions. Thus, **7** was selectively deacetylated at the anomeric position (DTT³⁵) and then the free thiol **30** was used in the reaction with **4a** (Scheme 7). When using the free thiol, a nucleophilic base is no longer needed and a sub-stoichiometric amount (0.3 mol equiv.) of the bulky non-nucleophilic base iPr₂NEt (DIPEA) was used. Both the β - and α -isomers were still formed in 3 : 1 ratio (34% yield). In the absence of base, no product was formed and the β -configuration of the starting thiol was preserved, which indicates that formation of the thiolate is required for both the aziridine opening reaction and the isomerization.

Upon suggestion of a referee, we also examined whether the presence of aziridine **4** has an influence on the anomerization process. To this end, β -Glc thioacetate **7** was treated with Et₂NH (1.5 mol equiv.) in DMF overnight and, upon quenching, a mixture of 2 stereoisomeric disulphides was identified in the crude reaction product. This result is indeed expected, based on the anomeric isomerization mechanism proposed in Scheme 6. However, when the thiol **30** was dissolved in degassed DMF and treated with 23% DIPEA for 5 h, it was recovered unchanged. Upon addition of the aziridine **4** to the reaction mixture, formation of both β -**24** and α -**24** was observed in the reaction crude. Thus, the anomerization mechanism of the thiol/thiolate appears to be somewhat more complex than suggested in Scheme 6 and strongly dependent on the reaction conditions. This aspect will surely deserve further investigations, that we will report in due course.

In conclusion, the highest yields of aziridine opening product **24** were obtained using the reaction conditions developed for mannose and operating at room temperature. Under these conditions, a high isomerization rate was observed. Performing the reaction at 0 °C, improved the β -**24** : α -**24** ratio to synthetically useful levels (10 : 1), but reduced the yield to 34%, due to extensive formation of the disulphide dimer. For all the other *thio*-glycosides, thus, we stuck to the conditions adopted for mannose, adjusting the reaction temperature as






Scheme 5 Scope of the aziridine opening reaction.

required by the reactivity of the individual substrate (see Table 2).

Further exploring the scope of the reaction, the GlcNAc derivative **11** (Scheme 5) gave *ca.* 19% of a 2 : 1 β : α mixture at room temperature (Table 2, entry 9). At 0 °C, the β : α ratio improved marginally (3 : 1) and the yields of the reaction became so low that it was not worth optimizing further. Surprisingly, the anomeric isomerization of β -galactose **8** and β -lactose **9** showed lower dependence on temperature in the interval examined (0 °C to room temperature) and 20%–30% of the α -isomer was formed in all cases (Table 2, entries 5 and 6). The reaction of the *N*-acetylneuraminic acid derivative **10** was complicated by the heterogeneity of the starting material. Thioacetylation of Neu5Ac is known to yield a basically inse-

parable mixture of products which contains the expected α -thioacetate **10** (Scheme 5), together with the glycal and acetyl disulphide products.³⁶ Using this mixture in the aziridine opening reaction afforded a crude which, upon chromatographic purification, yielded **27** (56%), together with *ca.* 17% glycal (Table 2, entry 8). The mixture was purified by HPLC for analytical purposes and NMR analysis confirmed that **27** was obtained as a single α -anomer, as shown by the signal of the H_{3eq} proton, which appears at 2.70 ppm as a doublet of doublet ($J_{\text{gem}} = 12.8$ Hz, $J_{3\text{eq-4}} = 4.5$ Hz)³⁷ and by the signal of the C1 carbon in a proton not decoupled ¹³C NMR spectra, which appears at 168.4 ppm as a doublet of quartets with a coupling constant $J_{\text{C1-H3ax}} = 3.9$ Hz (see ESI†).³⁸ Thus, as for mannose and rhamnose, the Neu5Ac thiol is configurationally





Scheme 6 Mechanism of the aziridine opening reaction.

Table 1 Opening reaction of aziridine **4a** with 1-S-acetyl- β -D-glucopyranose **7**^a

Entry	T (°C)	Et ₂ NH (mol equiv.)	β - 24 : α - 24 ^b	Yield ^c (%)	29 ^b (%)
1	20	1.9	2 : 1	61	<5
2	20	1.4	2 : 1	43	37
3	0	1.9	10 : 1	34	41
4	0	1.4	10 : 1	28	61
5 ^d	0	1.9	10 : 1	24	63
6 ^e	20	1.9	20 : 1	16	71

^a Unless otherwise noted, all reactions were performed on a 0.06 mmol scale, with a 0.65 M concentration of **4a** in DMF and 1.3 mol equiv. of **7** for 4 h with the amount of base and at the temperature indicated.

^b As judged by ¹H NMR of the crude. ^c Isolated, combined yields of the two anomeric products **24**. ^d 0.3 M concentration of **4a**. ^e Reaction performed in CH₂Cl₂.


stable under the reaction conditions. The results obtained in the screening (yields, anomeric ratios and optimal reaction conditions) for the glycosyl *thio*-acetates **1** and **6–11** are summarized in Table 2.

Finally, the *thio*-rhamno conjugate **23** was successfully used in the preparation of an *N*-linked pseudo-glycosylaminoacid scaffold, a viable building block for solid phase pseudo-glycopeptide synthesis (Scheme 8). After removal of the Boc protecting group (TFA, quant), the resulting amine was coupled in solution with the side chain carboxy group of an appropriately protected glutamic acid **32**, using HATU as the coupling agent. The pseudo-glycosylaminoacid **33** was isolated in 92% yield after chromatography.

Discussion and conclusions

A new synthetic approach was devised for the synthesis of *thio*-glycosides with the structure of *N*-linked pseudo-disaccharides through aziridine opening. In the developed procedure, formation of the thiol and opening of the aziridine are combined in a one-pot reaction, providing an efficient and operationally simple alternative to classical glycosylation methods. Under the conditions of the aziridine opening reaction, glycosyl thiols of glucose, *N*-acetylglucosamine, galactose and lactose





Scheme 7 Model studies with glucose derivative 7. Two step conditions: synthesis of the free thiol 30 and reaction with 4a.

Table 2 Scope of the aziridine opening reaction^a

Entry	Sugar	T (°C)	Product	β/α ratio ^b (yield % ^c)
1	Man 1	20	5a	α only (82)
2	Rha 6	20	23	α only (92)
3	Glc 7	0	24	10 : 1 (34)
4	Glc 7	20	24	2 : 1 (61)
5	Gal 8	0	25	4.5 : 1 (36)
6	Gal 8	20	25	3 : 1 (44)
7	Lac 9	0	26	5 : 1 (42)
8	Neu5Ac 10	20	27	α only (56) ^d
9	GlcNAc 11	20	28	2 : 1 (19)


^a All reactions were performed with a 0.65 M concentration of aziridine 4a and 1.9 mol equiv. of Et₂NH in DMF, at the indicated temperature.

^b Evaluated by ¹H NMR. ^c Isolated, both isomers. ^d Contains 17% glycal.

showed anomeric isomerization. Particularly for glucose, the anomeric isomerization proved to be temperature, base and solvent dependant. As one of the main advantages of glycosyl thiols is that – once formed – they are believed to retain their anomeric configuration, the finding is of high importance for future studies on *thio*-derivatives of carbohydrates.

In principle, there are two major pathways through which anomeric isomerization of glycosyl thiols can occur, mutarotation or Lewis acids promoted epimerization. While the mutarotation process of reducing sugars (1-hydroxyaldoses) has been extensively explored, the mutarotation of glycosyl thiols still

remains relatively unclear. The configurational stability of glycosyl thiols could be partially explained by poor orbital overlap between the anomeric carbon and the sulphur atom, which does not favor opening and subsequent mutarotation of the pyranose ring.³⁹ However, it was shown that in aqueous media mutarotation of free glycosyl thiols occurs at lower and neutral pH, while it is almost completely blocked under basic conditions. An exception is 1-*thio*-D-mannopyranose that was observed to mutarotate under both acidic and basic conditions.⁴⁰ The pH dependence of mutarotation is a result of steric, electronic (anomeric) and solvation effects. Accordingly, there are a few reports of mutarotation during 1-S-glycosylation and similar reactions.^{39,41,42} Anomerization of glycosyl thiols was also noticed in reactions with Lewis acids such as TiCl₄ and SnCl₄. In uronic acids such anomerization is particularly fast, presumably favoured by coordination of the C-1 heteroatom and C-6 carbonyl group to the Lewis acid. However, conditions have been found to exploit protecting groups to achieve similar results with many other monosaccharides.^{43,44} To the best of our knowledge, anomeric epimerization under (slightly) basic conditions such as the ones employed in our system has never been observed. Yet our data clearly show that it occurs for all the β-glycosyl thiols that we have examined, at least in DMF. The configurational stability observed for α-mannosyl and α-rhamnosyl thiols may be related to the axial configuration of the C2 hydroxy group, an element which is known to affect anomerization equilibria.⁴⁵



Scheme 8 Synthesis of 33, a building block for solid phase pseudo-glycopeptide synthesis.



The mechanism and the origin of stereoselectivity in this reaction will deserve further attention.

Despite this unforeseen hurdle, the one-pot aziridine opening reaction by glycosyl *thio*-acetates could be used in a number of cases, including mannose, rhamnose and Neu5Ac, to synthesize in good-to-acceptable yields mimics of *thio*-disaccharides outfitted with a *N*-linked tether. These molecules are equipped for easy conjugation and, at the same time, characterized by hydrolytic stability both of the *thio*-glycosidic linkage and of the conjugation handle. As an example, we described here the *thio*-mannosyl derivatives **5b–d**, which are fully hydrolytically stable analogues of Man α (1,2)Man ready for conjugation. The of Man α (1,2)Man disaccharide is a well-known binding epitope of immune system C-type lectins, including DC-SIGN.^{17,23} We also described the *thio*-rhamnosylated glutamic acid derivative **33**, which can be used in the synthesis of pseudo-rhamnopeptides. Rhamnosyl glycoconjugates have been recently described as important tools for the development of novel immunotherapeutics.^{46–51}

Carbohydrate-binding proteins (lectins) have been difficult to target selectively, since they often share broad selectivity for individual monosaccharides. One of the effective strategies described so far uses a monosaccharide, acting as the lectin anchor and connected to an aglycone. The aglycone is designed to host additional functionalities and orient them to secondary interaction sites in the lectin binding region, which are often more easily differentiated between different protein targets.⁵² We believe that the synthetic approach described in this paper, which exploits the expeditious glycosylation of aziridine-containing scaffolds, will be instrumental for the fast synthesis of (pseudo)-glycosylated libraries of compounds that could be used for the identification of selective lectin ligands.

Experimental section

General

Chemicals were purchased from commercial sources and used without further purification, unless otherwise indicated. When anhydrous conditions were required, the reactions were performed under nitrogen or argon atmosphere. Anhydrous solvents were purchased from Sigma-Aldrich® with a content of water $\leq 0.005\%$. Triethylamine (TEA), methanol and dichloromethane were dried over calcium hydride, THF was dried over sodium/benzophenone and freshly distilled. *N,N*-Dimethylformamide (DMF) was dried over 4 Å molecular sieves. Reactions were monitored by analytical thin-layer chromatography (TLC) performed on Silica Gel 60 F₂₅₄ plates (Merck), and TLC Silica gel 60 RP-18 F₂₅₄s (Merck) with UV detection (254 nm and 365 nm) and/or staining with ammonium molybdate acid solution, potassium permanganate alkaline solution or ninhydrin. Flash column chromatography was performed using silica gel 60 (40–63 μm , Merck). Automated flash chromatography was performed with Biotage Isolera Prime system and SNAP ULTRA cartridges were employed. Microwave irradiation was performed by a Biotage

Initiator⁺ system. NMR experiments were recorded on a Bruker AVANCE-400 MHz instrument at 298 K. Chemical shifts (δ) are reported in ppm. The ¹H and ¹³C NMR resonances of compounds were assigned with the assistance of COSY, HSQC and in some cases NOESY experiments. Multiplicities are assigned as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), mult. (for multiplets encompassing more than one proton).

Mass spectra were recorded on Apex II ICR FTMS (ESI ionization-HRMS), Waters Micromass Q-TOF (ESI ionization-HRMS) or Thermo Fischer LCQ apparatus (ESI ionization). The mass spectrometer was operated with electrospray ionization in the positive ion mode. Full-scan mass spectra were recorded in the mass/charge (*m/z*) range of 50–2000. Liquid chromatography-mass spectrometry (LC-MS) analyses were carried out on a Thermo Fisher LCQ Fleet ion trap mass spectrometer equipped with a UPLC UltiMate™ 3000 system containing UV detector. A Zorbax RX-C18 (2.1 \times 150 mm–5 μm) was used as column. The column oven was maintained at 30 °C. 5 μL of each sample solution were eluted using a binary gradient elution consisting of 0.1% formic acid in water (solvent A) and 0.1% formic acid in acetonitrile (solvent B) as follows: from 2% to 95% B in 25 min, 95% B kept for 10 min, then the eluent composition was brought at 2% B in 5 min. The flow rate was 0.25 mL min⁻¹. The mass spectrometer was operated with electrospray ionization in the positive ion mode. Full-scan mass spectra were recorded in the mass/charge (*m/z*) range of 50–2000. Specific optical rotation values were measured using a Perkin-Elmer 241, at 589 nm in a 1 dm cell. The following abbreviations are used: DCC (*N,N'*-dicyclohexylcarbodiimide), DMF (*N,N'*-dimethylformamide), DMAP (4-dimethylaminopyridine), TFA (trifluoroacetic acid), DPH (2,4-dinitrophenylhydroxylamine **15**), Rh₂(esp)₂ (Du Bois' catalyst **14**), Hex (hexane). The olefin **12** was synthesized as previously described.²³ The peracetylated glycosyl *thio*-acetates **1–9** were obtained as described in ref.^{20,21} The Neu5Ac and GlcNAc derivatives **10** and **11** were synthesized according to ref. 22. Experimental details and characterization of these known compounds are reported as ESI.†

Synthesis of aziridine 13

The reaction was performed in previously well-dried glassware flushed with Ar. Olefin **12** (200 mg, 1.01 mmol) was dissolved in CF₃CH₂OH (6.7 ml, 0.15 M) and transferred into the flask under Ar. The solution was cooled to 0 °C and then Rh₂(esp)₂ (7.7 mg, 0.010 mmol) and DPH (241 mg, 1.21 mmol) were added. The reaction mixture was stirred at 0 °C (ice bath) under Ar atmosphere for 6 h. After 3 h additional portions of Rh₂(esp)₂ (7.7 mg, 0.010 mmol) and DPH (40 mg, 0.20 mmol) were added. After 6 h the reaction mixture was diluted with CH₂Cl₂ (10 ml) and washed with sat. NaHCO₃ (10 ml), then H₂O was added (10 ml) to dissolve any forming salts. The aqueous phase was washed twice with CH₂Cl₂. Combined organic phases were washed with brine and dried over Na₂SO₄, filtered and concentrated under vacuum. The crude product was used directly and without further purification in the *N*-protection reaction to avoid decomposition and dimeriza-



tion that occur during chromatographic purification. For analytical purposes, chromatographic purification (95 : 5 CH₂Cl₂ : MeOH) was performed on a batch obtaining aziridine **13** in 68% (110 mg, 0.52 mmol) yield starting from 150 mg of olefin **12**. $R_f = 0.2$ (CH₂Cl₂/MeOH 95 : 5); ¹H NMR (400 MHz, CDCl₃): δ 3.66 (s, 3H, OMe), 3.64 (s, 3H, OMe), 2.78 (td, $J_{1-6ax} = J_{1-2} = 11.4$ Hz, $J_{1-6eq} = 4.6$ Hz, 1H, H₁), 2.54 (td, $J_{2-1} = J_{2-3ax} = 11.4$ Hz, $J_{2-3eq} = 6.5$ Hz, 1H, H₂), 2.39–2.33 (mult., 4H, H_{3eq}, H_{6eq}, H₄, H₅), 1.86–1.72 (mult., 2H, H_{3ax}, H_{6ax}); ¹³C NMR (100 MHz, CDCl₃): δ 175.9 (CO), 175.0 (CO), 51.9 (OMe), 51.9 (OMe), 41.3 (C₂), 38.2 (C₁), 29.7 (C₄), 28.0 (C₆), 27.5 (C₃), 27.2 (C₅); MS (ESI) calcd for C₁₀H₁₅NO₄ [M + H]⁺ m/z : 214.11; found m/z : 214.11.

The dimer **16** was also isolated by chromatography. Characterization of the dimer **16**: $R_f = 0.39$ (CH₂Cl₂/MeOH 9 : 1); ¹H NMR (400 MHz, CDCl₃): δ 3.71–3.64 (mult., 12H, OMe), 3.21 (td, $J_{1-6ax} = J_{1-2} = 9.9$ Hz, $J_{1-6eq} = 4.4$ Hz, 1H, H₁), 3.10–3.01 (mult., 2H, H₂, H₄), 2.80 (td, $J_{10-9ax} = J_{10-11} = 10.3$ Hz, $J_{10-9eq} = 5.0$ Hz, 1H, H₁₀), 2.52 (td, $J_{11-12ax} = J_{11-10} = 10.3$ Hz, $J_{11-12eq} = 6.3$ Hz, 1H, H₁₁), 2.34–2.14 (mult., 3H, H_{12eq}, H_{9eq}, H_{3eq}), 1.96–1.66 (mult., 5H, H_{12ax}, H_{6eq}, H_{6ax}, H_{9ax}, H_{3ax}), 1.66–1.60 (m, 1H, H₇), 1.37–1.31 (m, 1H, H₅); ¹³C NMR (100 MHz, CDCl₃): δ 175.9 (CO), 175.70 (CO), 175.3 (CO), 174.9 (CO), 69.4 (C₅), 52.2 (2 × OMe), 52.1 (2 × OMe), 50.0 (C₄), 41.1 (C₁), 40.1 (C₁₀), 39.5 (C₂), 39.0 (C₁₁), 38.6 (C₇), 34.5 (C₈), 31.7 (C₆), 28.4 (C₃), 27.9 (C₉), 27.2 (C₁₂); MS (ESI) calcd for C₂₀H₃₀N₂O₈ [M + H]⁺ m/z : 427.21; found m/z : 427.59.

Synthesis of the *N*-Boc-aziridine **4a**

To a solution of the free aziridine **13** (crude from the previous step, 1.01 mmol) dissolved in freshly distilled CH₂Cl₂ under N₂ atmosphere, DMAP (a few crystals) were added. The mixture was cooled to 0 °C and Et₃N (freshly distilled, 0.84 ml, 6.06 mmol) and Boc₂O (1.2 ml, 5.05 mmol) were added. After 1 h under stirring at 0 °C, the reaction was allowed to reach room temperature, then quenched with H₂O. The resulting mixture was diluted with a saturated solution of NH₄Cl; the aqueous phase extracted twice with EtOAc. The organic layers were washed with saturated solutions of KHSO₄, Na₂CO₃ and NaCl in this order and finally dried over Na₂SO₄, filtered and concentrated in *vacuum*. Purification by flash chromatography (7 : 3 Hex : EtOAc) afforded the *t*-butylcarbamate **4a** as a yellow waxy solid in 90% yield (0.29 g, 0.91 mmol). $R_f = 0.33$ (Hex/EtOAc 7 : 3); $[\alpha]_D^{26}$ (CHCl₃, *c* 1.05): +34; ¹H NMR (400 MHz, CDCl₃): δ 3.66 (s, 3H, OMe), 3.65 (s, 3H, OMe), 2.82 (td, $J_{1-6ax} = J_{1-2} = 11.5$ Hz, $J_{1-6eq} = 4.5$ Hz, 1H, H₁), 2.72–2.67 (m, 1H, H₅), 2.62 (td, $J_{4-3eq} = J_{4-5} = 6.4$ Hz, $J_{4-3ax} = 1.0$ Hz, 1H, H₄), 2.54 (td, $J_{2-1} = J_{2-3ax} = 11.5$ Hz, $J_{2-3eq} = 6.4$ Hz, 1H, H₂), 2.45 (ddd, $J_{6eq-6ax} = 14.2$ Hz, $J_{6eq-1} = 4.6$ Hz, $J_{6eq-5} = 1.6$ Hz, 1H, H_{6eq}), 2.35 (dt, $J_{3eq-3ax} = 14.9$ Hz, $J_{3eq-4} = J_{3eq-2} = 6.4$ Hz, 1H, H_{3eq}), 1.95 (ddd, $J_{3ax-3eq} = 14.9$ Hz, $J_{3ax-2} = 11.8$ Hz, $J_{3ax-4} = 1.0$ Hz, 1H, H_{3ax}), 1.74 (ddd, $J_{6ax-6eq} = 14.5$ Hz, $J_{6ax-1} = 11.4$ Hz, $J_{6ax-5} = 3.0$ Hz, 1H, H_{6ax}), 1.43 (s, 9H, *t*Bu); ¹³C NMR (100 MHz, CDCl₃): δ 175.4 (CO), 174.5 (CO), 162.3 (CO, carbamate), 81.3 (C_{IV} Boc), 52.0 (2 × OMe), 40.8 (C₂), 38.3 (C₁), 37.0 (C₅), 34.5 (C₄), 28.0 (*t*Bu 3 ×

Me), 27.5 (C₆), 26.3 (C₃); MS (ESI) calcd for C₁₅H₂₃NO₆ [M + Na]⁺ m/z : 336.14; found m/z : 336.18.

Synthesis of *N*-acyl-aziridine **4b**

To a solution of the free aziridine **13** (32 mg, 0.15 mmol) in dry THF (750 μl, 0.2 M), 3-chloropropionic acid **17** (19.5 mg, 0.18 mmol) and DCC (37 mg, 0.18 mmol) were added at room temperature. After 2.5 h, the white precipitate was filtered over celite, washing with CH₂Cl₂ and finally the solvents were removed under reduced pressure. Amide **4b** was isolated through a chromatographic column (1 : 1 Hex : EtOAc) in 73% yield (34 mg, 0.11 mmol). $R_f = 0.3$ (Hex/EtOAc 1 : 1); ¹H NMR (400 MHz, CDCl₃): δ 3.77 (t, $J_{8-7} = 6.4$ Hz, 2H, CH₂Cl), 3.68 (s, 3H, OMe), 3.67 (s, 3H, OMe), 2.91–2.78 (mult., 5H, H₄, H₅, H₁, CH₂-linker), 2.64 (ddd, $J_{2-3ax} = J_{2-1} = 11.1$ Hz, $J_{2-3eq} = 6.6$ Hz, 1H, H₂), 2.44 (ddd, $J_{6eq-6ax} = 14.3$ Hz, $J_{6eq-1} = 4.2$ Hz, $J_{6eq-5} = 1.3$ Hz, 1H, H_{6eq}), 2.36 (dt, $J_{3eq-3ax} = 14.8$ Hz, $J_{3eq-2} = J_{3eq-4} = 6.4$ Hz, 1H, H_{3eq}), 2.03 (ddd, $J_{3ax-3eq} = 15.1$ Hz, $J_{3ax-2} = 10.8$ Hz, $J_{3ax-4} = 0.7$ Hz, 1H, H_{3ax}), 1.88 (ddd, $J_{6ax-6eq} = 14$ Hz, $J_{6ax-1} = 10.2$ Hz, $J_{6ax-5} = 0.9$ Hz, 1H, H_{6ax}); MS (ESI) calcd for C₁₃H₁₈ClNO₅ [M + Na]⁺ m/z : 326.09 (100%), 328.07 (32%); found m/z : 326.38, 328.37.

Synthesis of *N*-acyl-aziridine **4c**

The free aziridine **13** (28 mg, 0.13 mmol) was dissolved in freshly distilled THF (650 μl). 3-Chloro-2,2-dimethylpropionic acid **18** (21 mg, 0.16 mmol) and DCC (32 mg, 0.16 mmol) were added in this order at room temperature and under nitrogen. After 4 h under stirring, the mixture was filtered over celite and washed with CH₂Cl₂. Flash chromatography (1 : 1 Hex : EtOAc) afforded the amide **4c** in 67% yield (29 mg, 0.087 mmol). $R_f = 0.4$ (Hex/EtOAc 1 : 1); ¹H NMR (400 MHz, CDCl₃): δ 3.69 (s, 3H, OMe), 3.67 (s, 3H, OMe), 3.61 (AB system, $J_{app} = 14.7$ Hz, 2H, CH₂Cl), 2.93–2.82 (mult., 3H, H₄, H₅, H₁), 2.67 (td, $J_{2-3ax} = J_{2-1} = 10.1$ Hz, $J_{2-3eq} = 6.6$ Hz, 1H, H₂), 2.44 (ddd, $J_{6eq-6ax} = 14.5$ Hz, $J_{6eq-1} = 4.8$ Hz, $J_{6eq-5} = 1.3$ Hz, 1H, H_{6eq}), 2.48–2.31 (m, 1H, H_{3eq}), 2.02 (ddd, $J_{3ax-3eq} = 14.5$ Hz, $J_{3ax-2} = 10.4$ Hz, $J_{3ax-4} = 1$ Hz, 1H, H_{3ax}), 1.9 (ddd, $J_{6ax-6eq} = 14$ Hz, $J_{6ax-1} = 11$ Hz, $J_{6ax-5} = 3.3$ Hz, 1H, H_{6ax}), 1.34 (s, 6H, 2 × CH₃ linker); ¹³C NMR (100 MHz, CDCl₃): δ 188.7 (CO amide), 174.9 (CO), 174.3 (CO), 52.0 (CH₂Cl), 52.0 (2 × OMe), 40.4 (C₂), 38.1 (C₁), 36.7 (C₅), 34.0 (C₄), 29.6 (CMe₂), 26.4 (C₆), 25.5 (C₃), 24.1, 23.9 (2 × CH₃ linker); MS (ESI) calcd for C₁₅H₂₂ClNO₅ [M + Na]⁺ m/z : 354.12 (100%), 356.11 (33%); found m/z : 354.43, 356.41.

Synthesis of the activated ester **20**

2,2-Dimethyl-3-chloro-propanoic acid **18** (400 mg, 2.97 mmol) was dissolved in dry DMF (14.6 ml) and NaN₃ (990 mg, 15.20 mmol) was added. The mixture was stirred at 50 °C under nitrogen atmosphere. After 3 days, the reaction was cooled to room temperature, diluted with CH₂Cl₂ and filtered over a celite pad to remove unreacted NaN₃ and the generated salts (NaCl). The solvent was evaporated at reduced pressure giving 3-azido-2,2-dimethylpropanoic acid **19** in quantitative yield (425 mg). ¹H NMR (400 MHz, CDCl₃): δ 3.42 (s, 2H, CH₂), 1.25 (s, 6H, 2 × CH₃).

To a solution of crude acid **19** (311 mg, 2.17 mmol) in dry DMF (7.2 ml, 0.3 M) *p*-nitrophenyl trifluoroacetate (766 mg,



3.25 mmol) and dry pyridine (350 μ l) were added. The mixture was warmed to 60 $^{\circ}$ C and stirred overnight. The following day, the reaction was cooled to room temperature and solvent and pyridine were removed under *vacuum*. Compound **20** was isolated in 73% (419 mg, 1.58 mmol) yield through a chromatographic column (8 : 2 Hex : EtOAc). R_f = 0.4 (Hex/EtOAc 8 : 2); ^1H NMR (400 MHz, CDCl_3): δ 8.28 (d, J = 8.9 Hz, 2H, H_{ar}), 7.27 (d, J = 9.2 Hz, 2H, H_{ar}), 3.57 (s, 2H, CH_2N_3), 1.4 (s, 6H, $2 \times \text{CH}_3$); ^{13}C NMR (100 MHz, CDCl_3): δ 173.5 (CO), 155.5 (C_{ar}), 145.6 (C_{ar}), 125.3 ($2 \times \text{CH}_{\text{ar}}$), 122.5 ($2 \times \text{CH}_{\text{ar}}$), 59.59 (CH_2), 44.4 ($\text{C}(\text{CH}_3)_2$), 23.03 ($2 \times \text{CH}_3$).

Synthesis of *N*-acyl-aziridine **4d**

Using DCC: To a solution of **13** (38 mg, 0.18 mmol) in dry THF (890 μ l, 0.2 M), carboxylic acid **19** (31 mg, 0.21 mmol) was added and then DCC (44 mg, 0.21 mmol). After 3 h under stirring at room temperature, the mixture was filtered over celite and washed with CH_2Cl_2 . The chromatographic column afforded compound **4d** in 30% yield (18 mg, 0.053 mmol). **Using the activated ester **20**:** To a solution of aziridine **13** (39 mg, 0.18 mmol) in dry DMF (720 μ l, 0.25 M) and pyridine (18 μ l) the activated ester **20** (63 mg, 0.24 mmol) was added. The reaction proceeded at 60 $^{\circ}$ C under stirring for 3 h. The mixture was cooled to room temperature and then solvent and pyridine were removed under reduced pressure. Flash chromatography (1 : 1 Hex : EtOAc) allowed to isolate compound **4d** in 60% yield (36 mg, 0.11 mmol). R_f = 0.38 (Hex/EtOAc 1 : 1); ^1H NMR (400 MHz, CDCl_3): δ 3.69 (s, 3H, OMe), 3.67 (s, 3H, OMe), 3.43 (AB system, J_{app} = 14.7 Hz, 2H, CH_2N_3), 2.90–2.79 (mult., 3H, H_1 , H_5 , H_4), 2.66 (td, $J_{2-3\text{ax}} = J_{2-1} = 10.6$ Hz, $J_{2-3\text{eq}} = 6.7$ Hz, 1H, H_2), 2.44 (ddd, $J_{6\text{eq}-6\text{ax}} = 14.3$ Hz, $J_{6\text{eq}-1} = 4.8$ Hz, $J_{6\text{eq}-5} = 1.3$ Hz, 1H, $\text{H}_{6\text{eq}}$), 2.36 (ddd, $J_{3\text{eq}-3\text{ax}} = 15$ Hz, $J_{3\text{eq}-2} = 6.9$ Hz, $J_{3\text{eq}-4} = 6.4$ Hz, 1H, $\text{H}_{3\text{eq}}$), 2.01 (ddd, $J_{3\text{ax}-3\text{eq}} = 14.9$ Hz, $J_{3\text{ax}-2} = 10.7$ Hz, $J_{3\text{ax}-4} = 0.6$ Hz, 1H, $\text{H}_{3\text{ax}}$), 1.26 (s, 6H, $2 \times \text{CH}_3$ linker); ^{13}C NMR (100 MHz, CDCl_3): δ 189.5 (CO amide), 175.1 (CO), 174.4 (CO), 60.3 (CH_2N_3), 52.2 (OMe), 52.1 (OMe), 40.5 (C_2), 38.3 (C_1), 36.9 (C_5), 34.2 (C_4), 29.8 ($\text{C}(\text{CH}_3)_2$ linker), 26.6 (C_6), 25.7 (C_3), 23.9 (CH_3 linker), 23.7 (CH_3 linker); MS (ESI) calcd for $\text{C}_{15}\text{H}_{22}\text{N}_4\text{O}_5$ [$\text{M} + \text{Na}$] $^+$ m/z : 361.15; found m/z : 361.61.

General procedure for the opening reaction of aziridine **4a**

Peracetylated *thio*-glycoside (1.3 eq.) and aziridine (1 eq.) were dissolved in dry DMF (0.65 M) under N_2 atmosphere at the temperature indicated in Table 2 and Et_2NH (1.9 eq.) was added. The reaction mixture was stirred for 4 h at the temperature indicated in Table 2, then the reaction mixture was diluted with EtOAc and washed with 1 M HCl. The organic phase was washed three times with H_2O and the aqueous phases were additionally extracted with EtOAc. The combined organic phases were dried over Na_2SO_4 , filtered and concentrated under vacuum.

General method for deacetylation of the sugar moiety

The substrates were dissolved in a $\text{MeNH}_2/\text{EtOH}$ solution (4 M) at room temperature in order to have a final solution 0.05 M of the substrate. The reactions were monitored by reverse-phase

TLC (eluents based on different ratios of $\text{H}_2\text{O}/\text{MeOH}$) and, after completion, the solvent and the excess MeNH_2 were removed under reduced pressure. The products were separated from the *N*-methylacetamide by-product using automated flash chromatography (Ultra HP-Sphere C18 cartridges) in reverse phase (isocratic elution, 1 : 1 $\text{H}_2\text{O} : \text{MeOH}$).

Synthesis of the pseudo-*thio*-dimannoside **5a**

Prepared from peracetylated *thio*-mannose **1** (37 mg, 0.091 mmol) and aziridine **4a** (22 mg, 0.070 mmol) according to the general procedure and purified by flash chromatography (1 : 1 Hex : EtOAc) to give **5a** in 82% yield (39 mg, 0.058 mmol). R_f = 0.33 (Hex/EtOAc 1 : 1); $[\alpha]_{\text{D}}^{19}$ (CHCl_3 , c 1.95): +59; ^1H NMR (400 MHz, CDCl_3): δ 5.40–5.34 (mult., 2H, H_1 , H_2), 5.30 (dd, $J_{4-5} = 10.2$ Hz, $J_{4-3} = 9.8$ Hz, 1H, H_4), 5.21 (dd, $J_{3-4} = 9.8$ Hz, $J_{3-2} = 2.9$ Hz, 1H, H_3), 4.80–4.70 (m, 1H, NH), 4.44–4.29 (mult., 2H, H_5 , $\text{H}_{6\text{a}}$), 4.17–4.07 (m, 1H, $\text{H}_{6\text{b}}$), 3.95–3.83 (m, 1H, $\text{H}_{4'}$), 3.71 (s, 3H, OMe), 3.70 (s, 3H, OMe), 3.31–3.21 (m, 1H, $\text{H}_{5'}$), 3.09–3.00 (m, 1H, $\text{H}_{1'}$), 2.88–2.77 (m, 1H, $\text{H}_{2'}$), 2.21–1.95 (mult., 3H, $\text{H}_{6'\text{eq}}$, $\text{H}_{3'\text{eq}}$, $\text{H}_{6'\text{ax}}$), 2.16 (s, 3H, OAc), 2.08 (s, 3H, OAc), 2.04 (s, 3H, OAc), 1.98 (s, 3H, OAc), 1.91–1.80 (m, 1H, $\text{H}_{3'}$, ax), 1.43 (s, 9H, *t*Bu); ^{13}C NMR (100 MHz, CDCl_3): δ 173.7 (CO), 173.7 (CO), 170.6 (CO), 169.9 (CO), 169.9 (CO), 169.7 (CO), 169.6 (CO, carbamate), 82.1 (C_1), 80.0 (C_{IV} Boc), 70.9 (C_2), 69.4 (C_3), 69.3 (C_5), 66.1 (C_4), 62.5 (C_6), 52.3 (OMe), 52.2 (OMe), 49.0 ($\text{C}_{4'}$), 44.5 ($\text{C}_{5'}$), 39.9 ($\text{C}_{1'}$, $\text{C}_{2'}$), 29.7 ($\text{C}_{6'}$), 29.1 ($\text{C}_{3'}$), 28.3 (*t*Bu, $3 \times \text{Me}$), 20.9 (OAc), 20.7 (OAc), 20.7 (OAc), 20.6 (OAc); MS (ESI) calcd for $\text{C}_{29}\text{H}_{43}\text{NO}_{15}\text{S}$ [$\text{M} + \text{Na}$] $^+$ m/z : 700.24; found m/z : 701.01.

Product **5a** (19 mg, 0.028 mmol) was deacetylated following the general procedure for deacetylation (reaction time 4 h). The deacetylated product was obtained after purification in 70% yield (10 mg, 0.020 mmol). R_f = 0.24 ($\text{H}_2\text{O}/\text{MeOH}$ 1 : 1) $[\alpha]_{\text{D}}^{18}$ (MeOH , c 0.5): +113; ^1H NMR (400 MHz, CD_3OD): δ 5.34 (d, $J_{1-2} = 1$ Hz, 1H, H_1), 3.96–3.81 (mult., 4H, H_2 , H_5 , H_4 , $\text{H}_{6\text{a}}$), 3.78–3.71 (dd, 1H, $J_{6\text{a}-6\text{b}} = 12.5$ Hz, $J_{6\text{b}-5} = 5.8$ Hz, $\text{H}_{6\text{b}}$), 3.68 (s, 3H, OMe), 3.68 (s, 3H, OMe), 3.66–3.59 (mult., 2H, H_4 , H_3), 3.24–3.17 (m, 1H, $\text{H}_{5'}$), 3.06–2.94 (mult., 2H, H_1 , H_2), 2.25–2.11 (m, 1H, $\text{H}_{6'\text{eq}}$), 2.11–1.97 (mult., 2H, $\text{H}_{6'\text{ax}}$, $\text{H}_{3'\text{eq}}$), 1.9–1.8 (m, 1H, $\text{H}_{3'\text{ax}}$), 1.45 (s, 9H, *t*Bu); ^{13}C NMR (100 MHz, CD_3OD): δ 176.1 (CO), 176.0 (CO), 157.2 (CO, carbamate), 86.4 (C_1), 80.4 (C_{IV} Boc), 75.4 (C_5), 73.8 (C_2), 73.2 (C_3), 68.8 (C_4), 62.9 (C_6), 52.5 ($2 \times \text{OMe}$), 50.7 ($\text{C}_{4'}$), 46.0 ($\text{C}_{5'}$), 41.5 ($\text{C}_{1'}$), 41.0 ($\text{C}_{2'}$), 30.3 ($\text{C}_{6'}$), 30.3 ($\text{C}_{3'}$), 28.8 (*t*Bu, $3 \times \text{Me}$). MS (ESI) calcd for $\text{C}_{21}\text{H}_{35}\text{NO}_{11}\text{S}$ [$\text{M} + \text{Na}$] $^+$ m/z : 532.18; found: 532.51; HR-MS (ESI) calcd for $\text{C}_{21}\text{H}_{35}\text{NO}_{11}\text{S}$ [$\text{M} + \text{Na}$] $^+$ m/z : 532.1829; found 532.1835.

Synthesis of the pseudo *thio*-disaccharide **23**

Prepared from peracetylated *thio*-rhamnose **6** (126 mg, 0.36 mmol) and aziridine **4a** (87 mg, 0.28 mmol) according to the general procedure and purified by automated flash chromatography (Biotage Isolera, SNAP Cartridge, gradient 30–50% EtOAc/Hex) to give **23** as a single α isomer in 92% yield (158 mg, 0.26 mmol) as colourless oil. R_f = 0.34 (Hex/EtOAc 1 : 1); $[\alpha]_{\text{D}}^{21}$ (CHCl_3 , c 1.00): –71; ^1H NMR (400 MHz, CDCl_3) δ 5.37–5.31 (m, 1H, H_2), 5.31 (s, 1H, H_1), 5.19–5.11 (m, 1H, H_3),



5.13–5.03 (m, 1H, H₄), 4.79 (s, 1H, NH), 4.23 (dt, $J_{5-4} = 12.3$ Hz, $J_{5-Me} = 6.3$ Hz, 1H, H₅), 3.90–3.83 (m, 1H, H_{4'}), 3.70 (s, 3H, OMe), 3.68 (s, 3H, OMe), 3.35–3.28 (m, 1H, H₅), 3.05–2.99 (m, 1H, H_{1'}), 2.84–2.73 (m, 1H, H₂), 2.14 (s, 3H, OAc), 2.06 (s, 3H, OAc), 2.17–1.93 (mult., 3H, H_{3'}eq, H_{6'}ax, H_{6'}eq), 1.97 (s, 3H, OAc), 1.96–1.85 (m, 1H, H_{3'}ax), 1.43 (s, 9H, *t*Bu), 1.24 (d, $J_{Me-5} = 6.3$ Hz, 3H, Me); ¹³C NMR (101 MHz, CDCl₃) δ 175.0 (CO), 174.4 (CO), 170.4 (CO), 170.3 (CO), 170.3 (CO), 83.8 (C₁), 71.7 (C₂), 71.6 (C₄), 69.9 (C₃), 67.9 (C₅), 52.7 (OMe), 52.6 (OMe), 49.8 (C_{4'}), 45.7 (C_{5'}), 40.3 (C_{2'}), 40.1 (C_{1'}), 30.1 (C_{6'}), 29.3 (C_{3'}), 28.7 (*t*Bu-3 × Me), 21.3 (OAc), 21.2 (OAc), 21.1 (OAc), 17.6 (Me); $J_{H1-C1} = 170.3$ (HSQC without ¹³C decoupling); LC-MS ($R_t = 20.41$ min) calcd for C₂₇H₄₁NO₁₃S [M + Na]⁺ m/z : 642.23; found m/z : 641.78. MS (HRMS): calcd for C₂₇H₄₁NO₁₃S [M + Na]⁺ m/z : 642.2196; found m/z : 642.2195.

Synthesis of the pseudo *thio*-disaccharide 24

Prepared from peracetylated *thio*-glucose 7 (34 mg, 0.083 mmol) and aziridine 4a (20 mg, 0.064 mmol) according to the general procedure and purified by flash chromatography (1 : 1 Hex : EtOAc) to give 24 in 61% yield (26 mg, 0.039 mmol) as colourless oil (entry 4 in Table 2). The β and α isomers could be separated by flash chromatography (8 : 1 *i*Pr₂O : EtOAc). β-24: $R_f = 0.22$ (*i*Pr₂O/EtOAc 8 : 1); ¹H NMR (400 MHz, CDCl₃) δ 5.23 (dd, $J_{3-4} = J_{3-2} = 10$ Hz, 1H, H₃), 5.13 (dd, $J_{4-3} = J_{4-5} = 10$ Hz, 1H, H₄), 5.04 (dd, $J_{2-1} = J_{2-3} = 10$ Hz, 1H, H₂), 4.87 (m, 1H, NH), 4.72 (d, $J_{1-2} = 10$ Hz, 1H, H₁), 4.27 (dd, $J_{6a-6b} = 12.4$ Hz, $J_{6a-5} = 4.5$ Hz, 1H, H_{6a}), 4.15 (dd, $J_{6b-6a} = 12.4$ Hz, $J_{6b-5} = 2.4$ Hz, 1H, H_{6b}), 3.93–3.80 (m, 1H, H_{4'}), 3.76 (ddd, $J_{5-4} = 10.0$ Hz, $J_{5-6a} = 4.5$ Hz, $J_{5-6b} = 2.4$ Hz, 1H, H₅), 3.69 (s, 6H, 2 × OMe), 3.42–3.26 (m, 1H, H_{5'}), 2.99–2.86 (m, 1H, H_{1'}), 2.81–2.70 (m, 1H, H_{2'}), 2.24–2.08 (mult., 3H, H_{3'}eq, H_{6'}eq, H_{6'}ax), 2.07 (s, 3H, OAc), 2.05 (s, 3H, OAc), 2.02 (s, 3H, OAc), 2.00 (s, 3H, OAc), 1.91–1.81 (m, 1H, H_{3'}ax), 1.45 (s, 9H, *t*Bu); ¹³C NMR (101 MHz, CDCl₃) δ 174.0 (CO), 171.8 (CO), 171.7 (CO), 170.8 (CO), 170.3 (CO), 169.5 (CO), 83.7 (C₁), 76.0 (C₅), 74.1 (C₃), 70.2 (C₂), 68.3 (C₄), 62.0 (C₆), 52.4 (OMe), 52.3 (OMe), 48.2* (C_{4'}), 42.1* (C_{5'}), 40.1 (C_{1'}, C_{2'}), 29.8 (C_{3'}, C_{6'}), 28.5 (*t*Bu-3 × Me), 20.9 (OAc), 20.9 (OAc), 20.8 (OAc), 20.8 (OAc). * These signals are better visible in the HSQC spectrum; LC-MS ($R_t = 19.64$ min) calcd for C₂₉H₄₃NO₁₅S [M + Na]⁺ m/z : 700.24; found m/z : 699.81; MS (HRMS): calcd for C₂₉H₄₃NO₁₅S [M + Na]⁺ m/z : 700.2251; found m/z : 700.2249. α-24: ¹H NMR (400 MHz, CDCl₃) δ 5.73 (d, $J_{2-1} = 5.7$ Hz, 1H, H₁), 5.35 (dd, $J_{3-2} = J_{3-4} = 9.8$ Hz, 1H, H₃), 5.14–4.99 (mult., 2H, H₄, H₂), 4.75 (s, 1H, NH), 4.48–4.39 (m, 1H, H₅), 4.34 (dd, $J_{6a-6b} = 12.5$ Hz, $J_{6a-5} = 4.6$ Hz, 1H, H_{6a}), 4.19–4.09 (m, 1H, H_{6b}), 3.92–3.83 (m, 1H, H_{4'}), 3.71 (s, 3H, OMe), 3.70 (s, 3H, OMe), 3.24–3.15 (m, 1H, H_{5'}), 3.11–2.98 (m, 1H, H_{1'}), 2.88–2.73 (m, 1H, H_{2'}), 2.09 (s, 3H, OAc), 2.08 (s, 3H, OAc), 2.10–2.00 (mult., 3H, H_{3'}eq, H_{6'}eq, H_{6'}ax), 2.03 (s, 3H, OAc), 2.01 (s, 3H, OAc), 1.92–1.84 (m, 1H, H_{3'}ax), 1.44 (s, 9H, *t*Bu); ¹³C NMR (HSQC) (101 MHz, CDCl₃) δ 81.2 (C₁), 70.2 (C₃), 67.8 (C₅, C₂, C₄), 61.6 (C₆), 51.9 (2 × OMe), 49.2 (C_{4'}), 42.5 (C_{5'}), 39.7 (C_{1'}, C_{2'}), 29.0 (C_{3'}, C_{6'}), 29.0 (*t*Bu-3 × Me), 20.6 (4 × OAc); LC-MS ($R_t = 19.87$ min) calcd for C₂₉H₄₃NO₁₅S [M + Na]⁺ m/z : 700.24; found m/z : 699.81.

Synthesis of the pseudo *thio*-disaccharide 25

Prepared from peracetylated *thio*-galactose 8 (51 mg, 0.13 mmol) and aziridine 4a (30 mg, 0.096 mmol) according to the general procedure and purified by flash chromatography (1 : 1 Hex : EtOAc) to give 25 as a mixture of α and β isomers in 44% (29 mg, 0.042 mmol) yield as colourless oil. The β and α isomers were separated by a second flash chromatography (8 : 1 *i*Pr₂O : EtOAc) to give pure β-25 in 34% yield (22 mg, 0.033 mmol). β-25: $R_f = 0.33$ (*i*Pr₂O/EtOAc 8 : 2); ¹H NMR (400 MHz, CDCl₃) δ 5.45 (dd, $J_{4-3} = J_{4-5} = 3.4$ Hz, 1H, H₄), 5.24 (dd, $J_{2-1} = J_{2-3} = 10.0$ Hz, 1H, H₂), 5.05 (dd, $J_{3-2} = 10.0$ Hz, $J_{3-4} = 3.4$ Hz, 1H, H₃), 4.86 (m, 1H, NH), 4.69 (d, $J_{1-2} = 10.0$ Hz, 1H, H₁), 4.13 (mult., 2H, H_{6a}, H_{6b}), 3.98 (m, 1H, H₅), 3.87–3.77 (m, 1H, H_{4'}), 3.70 (s, 3H, OMe), 3.69 (s, 3H, OMe), 3.39–3.28 (m, 1H, H_{5'}), 3.02–2.93 (m, 1H, H_{1'}), 2.81–2.69 (m, 1H, H_{2'}), 2.17 (s, 3H, OAc), 2.14–2.09 (mult., 3H, H_{3'}eq, H_{6'}ax, H_{6'}eq), 2.04 (s, 3H, OAc), 2.03 (s, 3H, OAc), 1.98 (s, 3H, OAc), 1.89–1.82 (m, 1H, H_{3'}ax), 1.45 (s, 9H, *t*Bu); ¹³C NMR (101 MHz, CDCl₃) δ 174.0 (CO), 170.4 (CO), 170.4 (CO), 170.2 (CO), 170.1 (CO), 169.7 (CO), 84.4 (C₁), 74.5 (C₅), 72.0 (C₃), 67.5 (C₄), 67.3 (C₂), 61.3 (C₆), 52.3 (OMe), 52.2 (OMe), 49.7 (C_{4'}), 43.4 (C_{5'}), 40.0 (C_{2'}, C_{1'}), 29.8 (C_{3'}, C_{6'}), 28.5 (*t*Bu-3 × Me), 20.9 (OAc), 20.8 (OAc), 20.7 (OAc), 20.7 (OAc); LC-MS ($R_t = 19.51$ min) calcd for C₂₉H₄₃NO₁₅S [M + Na]⁺ m/z : 700.24; found m/z : 699.74; MS (HRMS): calcd for C₂₉H₄₃NO₁₅S [M + Na]⁺ m/z : 700.2251; found m/z : 700.2259.

Synthesis of the pseudo *thio*-disaccharide 26

Prepared from peracetylated *thio*-lactose 9 (56 mg, 0.080 mmol) and aziridine 4a (19 mg, 0.062 mmol) according to the general procedure and purified by flash chromatography (3 : 2 Hex : EtOAc) to give 26 as a 5 : 1 β : α anomeric mixture in 42% yield (25 mg, 0.026 mmol) as colourless oil. $R_f = 0.14$ (Hex/EtOAc 1 : 1); ¹H NMR (400 MHz, CDCl₃) β-26 5.35–5.33 (m, 1H, H₁₀), 5.21 (dd, $J_{3-4} = J_{3-2} = 9.2$ Hz, 1H, H₃), 5.10 (dd, $J_{8-9} = 10.4$ Hz, $J_{8-7} = 7.9$ Hz, 1H, H₈), 5.02–4.97 (m, 1H, H₂), 4.95 (dd, $J_{9-8} = 10.4$ Hz, $J_{9-10} = 3.2$ Hz, 1H, H₉), 4.86 (d, $J_{NH-4'} = 6.9$ Hz, 1H, NH), 4.67 (d, $J_{1\beta-2\beta} = 10.1$ Hz, 1H, H_{1\beta}), 4.49 (mult., 2H, H₇, H_{12a}), 4.15–4.01 (mult., 3H, H_{12b}, H_{6a}, H_{6b}), 3.91–3.81 (mult., 3H, H₁₁, H₄, H₅), 3.70 (s, 1H, H_{4'}), 3.68 (2 × s, 6H, 2 × OMe), 3.37–3.30 (m, 1H, H_{5'}), 2.96–2.87 (m, 1H, H_{1'}), 2.82–2.70 (m, 1H, H_{2'}), 2.15 (s, 3H, OAc), 2.09 (s, 3H, OAc), 2.12–2.05 (mult., 3H, H_{3'}eq, H_{6'}ax, H_{6'}eq), 2.06 (s, 6H, 2 × OAc), 2.04 (s, 9H, 3 × OAc), 1.96 (s, 3H, OAc), 1.89–1.81 (m, 1H, H_{3'}ax), 1.44 (s, 9H, *t*Bu), α-26 δ 5.62 (d, $J_{1\alpha-2\alpha} = 5.7$ Hz, 1H, H_{1\alpha}); β-26 ¹³C NMR (101 MHz, CDCl₃) δ 174.7 (CO), 174.0 (CO), 170.5 (CO), 170.4 (CO), 170.3 (CO), 170.2 (CO), 169.8 (CO), 169.8 (CO), 169.2 (CO), 83.5 (C₁), 76.8 (C₅), 76.1 (C₁₁), 74.0 (C₃), 71.2 (C₄), 70.8 (C₉), 70.5 (C₂), 69.2 (C₈), 66.7 (C₁₀), 62.1 (C₁₂), 60.9 (C₆), 52.3 (OMe), 52.2 (OMe), 49.7 (C_{4'}), 43.1 (C_{5'}), 40.1 (C_{1'}, C_{2'}), 32.1 (C_{6'}), 29.8 (C_{3'}), 28.5 (*t*Bu-3 × Me), 21.0 (OAc), 20.9 (OAc), 20.9 (OAc), 20.9 (OAc), 20.8 (OAc), 20.8 (OAc), 20.6 (OAc); LC-MS ($R_t = 20.56$ min (β), 20.66 min (α)) calcd for C₄₁H₅₉NO₂₃S [M + Na]⁺ m/z : 988.32; found m/z : 987.62; MS (HRMS): calcd for C₄₁H₅₉NO₂₃S [M + Na]⁺ m/z : 988.3096; found m/z : 988.3090.



Synthesis of the pseudo *thio*-disaccharide 27

Prepared from peracetylated *thio*-sialic acid **10**³⁶ (68 mg, 0.12 mmol) and aziridine **4a** (30 mg, 0.096 mmol) according to the general procedure and purified by flash chromatography (3 : 1 CH₂Cl₂ : acetone) to give **27** as a single isomer in 56% yield (containing 17% glycal as estimated by NMR) as yellow waxy solid. $R_f = 0.33$ (CH₂Cl₂ : acetone = 3 : 1); ¹H NMR (400 MHz, CDCl₃) δ 5.51–5.44 (m, 1H, H₇), 5.43–5.36 (mult., 2H, H₈, NH), 5.06 (d, $J = 11.0$ Hz, 1H, NH), 4.84 (td, $J_{4-5} = J_{4-3ax} = 11.0$ Hz, $J_{4-3eq} = 4.5$ Hz, 1H, H₄), 4.28–4.18 (m, 1H, H₉), 4.28–4.13 (mult., 2H, H_{9a}, H_{9b}), 4.02 (ddd, $J_{5-NH} = J_{5-4} = J_{5-6} = 11.0$ Hz, 1H, H₅), 3.91–3.86 (m, 1H, H₆), 3.85 (s, 3H, COOMe), 3.73 (s, 3H, COOMe), 3.71 (s, 3H, COOMe), 3.60–3.51 (m, 1H, H₄), 3.13–3.07 (m, 1H, H₅), 3.07–3.01 (m, 1H, H₁), 2.91–2.84 (m, 1H, H₂), 2.70 (dd, $J_{3eq-3ax} = 12.8$ Hz, $J_{3eq-4} = 4.5$ Hz, 1H, H_{3eq}), 2.20 (s, 3H, OAc), 2.14 (s, 3H, OAc), 2.06 (s, 3H, OAc), 2.18–2.04 (mult., 4H, H_{3'eq}, H_{3'ax}, H_{6'eq}, H_{6'ax}), 2.03 (s, 3H, OAc), 2.00–1.89 (m, 1H, H_{3ax}), 1.87 (s, 3H, NHAc), 1.47 (s, 9H, *t*Bu); ¹³C NMR (HSQC) (101 MHz, CDCl₃) δ 72.3 (C₆), 68.2 (C₄), 66.2 (C₇), 66.0 (C₈), 60.2 (C₉), 51.3 (OMe), 50.6 (OMe), 50.5 (OMe), 47.4 (C₅), 41.3 (C₂), 38.6 (C₁, C₅), 36.6 (C₃), 29.6 (C₃, C₆), 27.1 (*t*Bu-3 × Me), 21.8 (NHAc), 19.8 (Ac), 19.4 (Ac), 19.3 (2 × Ac); LC-MS ($R_t = 17.99$ min) calcd for C₃₅H₅₂N₂O₁₈S [M + Na]⁺ m/z : 843.29; found m/z : 842.71; MS (HRMS) calcd for C₃₅H₅₂N₂O₁₈S [M + Na]⁺ m/z : 843.2834; found m/z : 843.2820.

Synthesis of the pseudo *thio*-disaccharide 28

Prepared from peracetylated *thio*-*N*-acetylglucosamine **11** (34 mg, 0.083 mmol) and aziridine **4a** (20 mg, 0.064 mmol) according to the general procedure and purified by flash chromatography (9 : 1 CH₂Cl₂ : MeOH) to give **28** as an inseparable anomeric mixture in 19% yield (8 mg, 0.012 mmol) as yellow waxy solid. $R_f = 0.08$ (Hex/EtOAc 1 : 1); ¹H NMR (400 MHz, CDCl₃) β -**28** δ 5.63 (d, $J_{NH-2} = 9.3$ Hz, 1H, NH), 5.18–5.09 (mult., 2H, H₃, H₄), 4.92–4.84 (m, 1H, NH), 4.75 (d, $J_{1\beta-2\beta} = 10.4$ Hz, 1H, H_{1 β}), 4.40–4.34 (m, 1H, H₂), 4.26 (dd, $J_{6a-6b} = 12.1$ Hz, $J_{6a-5} = 4.3$ Hz, 1H, H_{6a}), 4.18–4.13 (m, 1H, H_{6b}), 3.92–3.79 (m, 1H, H₄), 3.76–3.74 (m, 1H, H₅), 3.71 (s, 3H, COOMe), 3.68 (s, 3H, COOMe), 3.35–3.30 (m, 1H, H₅), 2.97–2.90 (m, 1H, H₁), 2.75–2.68 (m, 1H, H₂), 2.13–2.01 (mult., 3H, H_{3'eq}, H_{6'ax}, H_{6'eq}), 2.09 (s, 3H, OAc), 2.04 (s, 3H, OAc), 2.03 (s, 3H, OAc), 2.02 (s, 3H, OAc), 1.98 (s, 3H, OAc), 1.88–1.83 (m, 1H, H_{3'ax}), 1.45 (s, 9H, Boc); α -**28** δ 5.52 (d, $J_{1\alpha-2\alpha} = 5.2$ Hz, 1H, H_{1 α}); ¹³C NMR (HSQC) (101 MHz, CDCl₃) δ 67.9 (C₃), 73.7 (C₄), 85.2 (C₁), 68.0 (C₂), 61.3 (C₆), 52.1 (OMe), 52.0 (OMe), 49.0 (C₄), 41.0 (C₅, C₂, C_{1'}), 29.1 (C_{6'}), 28.6 (C_{3'}), 28.4 (*t*Bu-3 × Me), 23.1 (NHAc), 20.8 (OAc), 20.6 (OAc), 20.7 (OAc); LC-MS ($R_t = 16.67$ min (β), 17.33 min (α)) calcd for C₂₉H₄₄N₂O₁₄S [M + Na]⁺ m/z : 699.25; found m/z : 698.75; MS (HRMS) calcd for C₂₉H₄₄N₂O₁₄S [M + Na]⁺ m/z : 699.2411; found m/z : 699.2413.

Synthesis of the pseudo-*thio*-dimannoside 5c

Prepared from peracetylated *thio*-mannose **1** (46 mg, 0.11 mmol) and aziridine **4c** (30 mg, 0.090 mmol) according to

the general procedure described for the synthesis of **5a** and purified by flash chromatography (1 : 1 Hex : EtOAc) to give **5c** in 96% yield (60 mg, 0.086 mmol). $R_f = 0.2$ (Hex/EtOAc 1 : 1); $[\alpha]_D^{19}$ (CHCl₃, c 1.22): +55; ¹H NMR (400 MHz, CDCl₃): δ 5.96–5.89 (m, 1H, NH), 5.41 (d, $J_{1-2} = 1.5$ Hz, 1H, H₁), 5.34 (dd, $J_{2-3} = 3.5$ Hz, $J_{2-1} = 1.5$ Hz, 1H, H₂), 5.29 (t, $J_{4-3} = J_{4-5} = 9.7$ Hz, 1H, H₄), 5.20 (dd, $J_{3-4} = 9.7$ Hz, $J_{3-2} = 3.5$, 1H, H₃), 4.42–4.30 (mult., 2H, H₅, H_{6a}), 4.21–4.07 (mult., 2H, H_{4'}, H_{6b}), 3.72 (s, 3H, OMe), 3.70 (s, 3H, OMe), 3.58 (AB system, $J_{app} = 10.7$ Hz, 2H, CH₂Cl), 3.33–3.27 (m, 1H, H₅), 3.08 (ddd, $J_{1'-2'} = 13.5$ Hz, $J_{1'-6'ax} = 8.8$ Hz, $J_{1'-6'eq} = 5.34$ Hz, 1H, H_{1'}), 2.87–2.78 (m, 1H, H_{2'}), 2.23 (ddd, $J_{3'eq-3'ax} = 14.1$ Hz, $J_{3'eq-2'} = 10$ Hz, $J_{3'eq-4'} = 4.4$ Hz, 1H, H_{3'eq}), 2.18–1.94 (mult., 2H, H_{6'eq}, H_{6'ax}), 2.15 (s, 3H, OAc), 2.07 (s, 3H, OAc), 2.04 (s, 3H, OAc), 1.97 (s, 3H, OAc), 1.92–1.82 (m, 1H, H_{3'ax}), 1.28 (s, 3H, CH₃ linker), 1.27 (s, 3H, CH₃ linker); ¹³C NMR (100 MHz, CDCl₃): δ 174.34 (CO), 174.22 (CO), 173.56 (CO), 170.76 (CO), 169.94 (CO), 169.83 (CO), 169.72 (CO), 81.80 (C₁), 70.95 (C₂), 69.52 (C₃), 69.44 (C₅), 66.26 (C₄), 62.59 (C₆), 60.4 (C(CH₃)₂ linker), 52.82 (CH₂ linker), 52.42 (OMe), 52.29 (OMe), 48.16 (C_{4'}), 43.67 (C_{5'}), 40.21 (C_{1'}), 40.03 (C_{2'}), 29.35 (C_{6'}), 28.76 (C_{3'}), 23.63 (CH₃ linker), 23.37 (CH₃ linker), 20.96 (OAc), 20.77 (OAc), 20.73 (OAc), 20.66 (OAc); MS (ESI) calcd for C₂₉H₄₂ClNO₁₄S [M + Na]⁺ m/z : 718.19; found m/z : 718.6.

Product **5c** (22 mg, 0.032 mmol) was deacetylated according to the general procedure for acetylation (reaction time 3 h). The deacetylated product was obtained in 62% (10.5 mg, 0.020 mmol) yield after purification. $R_f = 0.31$ (H₂O/MeOH 1 : 1) $[\alpha]_D^{20}$ (MeOH, c 0.47): +110; ¹H NMR (400 MHz, CD₃OD): δ 5.34 (d, $J_{1-2} = 1.2$ Hz, 1H, H₁), 4.1 (ddd, $J_{4'-3'ax} = 8.2$ Hz, $J_{4'-3'eq} = 7.3$ Hz, $J_{4'-5'} = 4.2$ Hz, 1H, H_{4'}), 3.93–3.82 (mult., 3H, H₅, H₂, H_{6a}), 3.77–3.56 (mult., 5H, H_{6b}, H₄, H₃, CH₂Cl), 3.72 (s, 3H, OMe), 3.71 (s, 3H, OMe), 3.22–3.15 (mult., 2H, H_{5'}, H_{2'}), 3.15–3.09 (m, 1H, H_{1'}), 2.34 (ddd, $J_{6'eq-6'ax} = 14.4$ Hz, $J_{6'eq-1'} = 7.7$ Hz, $J_{6'eq-5'} = 3.6$ Hz, 1H, H_{6'eq}), 2.19–2.10 (m, 1H, H_{3'eq}), 2.02 (ddd, $J_{6'ax-6'eq} = 14.2$ Hz, $J_{6'ax-5'} = 8.1$ Hz, $J_{6'ax-1'} = 4.3$ Hz, 1H, H_{6'ax}), 1.88 (ddd, $J_{3'ax-3'eq} = 14.2$ Hz, $J_{3'ax-4'} = 7.7$ Hz, $J_{3'ax-2'} = 4.7$ Hz, 1H, H_{3'ax}), 1.28 (s, 6H, 2 × CH₃ linker); ¹³C NMR (100 MHz, CD₃OD): δ 177.2 (CO), 175.7 (CO), 175.6 (CO), 85.3 (C₁), 75.5 (C₅), 73.9 (C₂), 73.3 (C₃), 68.9 (C₄), 63.0 (C₆), 53.5 (CH₂Cl), 52.8 (OMe), 52.7 (OMe), 49.9 (C_{4'}), 45.1 (C_{5'}), 42.0 (C_{1'}), 41.6 (C_{2'}), 31.4 (C_{6'}), 30.5 (C_{3'}), 24.0 (CH₃ linker), 23.8 (CH₃ linker); HR-MS (ESI) calcd for C₂₁H₃₄ClNO₁₀S [M + Na]⁺ m/z : 550.1490; found: 550.1495.

Synthesis of the pseudo-*thio*-dimannoside 5d

Thioacetate **1** (78 mg, 0.19 mmol) and aziridine **4d** (50 mg, 0.15 mmol) were dissolved in dry DMF (250 μ l, 0.6 M) into a MW-reactor. After addition of Et₂NH (30 μ l, 0.28 mmol), the reaction was stirred at 60 °C under MW irradiation for 1 h. After that, the mixture was diluted with EtOAc and washed with 1 M HCl. The aqueous phase was extracted twice with EtOAc and finally the organic layers collected were dried over Na₂SO₄, filtered and the solvents removed under vacuum. Compound **5d** was isolated through flash chromatography (1 : 1 Hex : EtOAc) in 68% yield (72 mg, 0.10 mmol). $R_f = 0.27$



(Hex/EtOAc 1 : 1); $[\alpha]_{\text{D}}^{18}$ (CHCl₃, *c* 1.55): +69; ¹H NMR (400 MHz, CDCl₃): δ 6.09–5.99 (m, 1H, NH), 5.41 (d, *J*₁₋₂ = 1.1 Hz, 1H, H₁), 5.33 (dd, *J*₂₋₃ = 3.3 Hz, *J*₂₋₁ = 1.1 Hz, 1H, H₂), 5.29 (t, *J*₄₋₃ = *J*₄₋₅ = 10.0 Hz, 1H, H₄), 5.20 (dd, *J*₃₋₄ = 10.0 Hz, *J*₃₋₂ = 3.3 Hz, 1H, H₃), 4.42–4.29 (mult., 2H, H₅, H_{6a}), 4.18–4.08 (mult., 2H, H_{4'}, H_{6b}), 3.72 (s, 3H, OMe), 3.71 (s, 3H, OMe), 3.40 (AB system, *J*_{app} = 15.0 Hz, 2H, CH₂N₃), 3.29–3.23 (m, 1H, H_{5'}), 3.08 (ddd, *J*_{1'-2'} = 12.6 Hz, *J*_{1'-6'ax} = 8.8 Hz, *J*_{1'-6'eq} = 4.2 Hz, 1H, H_{1'}), 2.90–2.80 (m, 1H, H_{2'}), 2.28–2.18 (m, H_{3'eq}), 2.18–2.00 (mult., 2H, H_{6'eq}, H_{6'ax}), 2.15 (s, 3H, OAc), 2.07 (s, 3H, OAc), 2.04 (s, 3H, OAc), 1.97 (s, 3H, OAc), 1.92–1.80 (m, 1H, H_{3'ax}), 1.20 (2 × s, 6H, 2 × CH₃ linker); ¹³C NMR (100 MHz, CDCl₃): δ 175.0 (CO), 174.2 (CO), 173.5 (CO), 170.7 (CO), 169.9 (CO), 169.8 (CO), 169.7 (CO), 81.8 (C₁), 71.0 (C₂), 69.5 (C₃), 69.5 (C₅), 66.3 (C₄), 62.6 (C₆), 60.0 (CH₂N₃), 52.4 (OMe), 52.3 (OMe), 48.0 (C_{4'}), 43.9 (C_{5'}), 40.2 (C_{1'}), 40.1 (C_{2'}), 29.5 (C_{6'}), 28.9 (C_{3'}), 23.4 (CH₃ linker), 23.4 (CH₃ linker), 20.1 (OAc), 20.7 (OAc), 20.7 (OAc), 20.7 (OAc); MS (ESI) calcd for C₂₉H₄₂N₄O₁₄ [M + Na]⁺ *m/z*: 725.23; found *m/z*: 725.66.

Product **5d** (31 mg, 0.044 mmol) was deacetylated according to the general procedure for deacetylation (reaction time 3 h). Deacetylated product was obtained in 68% (16 mg, 0.030 mmol) yield after purification. *R*_f = 0.21 (CH₂Cl₂/MeOH 9 : 1); $[\alpha]_{\text{D}}^{16}$ (MeOH, *c* 0.55): +105; ¹H NMR (400 MHz, CD₃OD): δ 5.34 (d, *J*₁₋₂ = 1.2 Hz, 1H, H₁), 4.1 (ddd, *J*_{4'-3'ax} = 8.1 Hz, *J*_{4'-3'eq} = 7.7 Hz, *J*_{4'-5'} = 4.1 Hz, 1H, H_{4'}), 3.93–3.82 (mult., 3H, H₅, H₂, H_{6a}), 3.78–3.67 (m, 1H, H_{6b}), 3.72 (s, 3H, OMe), 3.72 (s, 3H, OMe), 3.67–3.57 (mult., 2H, H₄, H₃), 3.44 (AB system, *J*_{app} = 15.7 Hz, 2H, CH₂N₃), 3.22–3.08 (mult., 3H, H_{5'}, H_{1'}, H_{2'}), 2.34 (ddd, *J*_{6'eq-6'ax} = 14.3 Hz, *J*_{6'eq-1'} = 7.7 Hz, *J*_{6'eq-5'} = 3.8 Hz, 1H, H_{6'eq}), 2.15 (ddd, *J*_{3'eq-3'ax} = 14 Hz, *J*_{3'eq-2'} = 7 Hz, *J*_{3'eq-4'} = 4 Hz, 1H, H_{3'eq}), 2.02 (ddd, *J*_{6'ax-6'eq} = 14.3 Hz, *J*_{6'ax-5'} = 7.9 Hz, *J*_{6'ax-1'} = 4.4 Hz, 1H, H_{6'ax}), 1.88 (ddd, *J*_{3'ax-3'eq} = 14.1 Hz, *J*_{3'ax-4'} = 7.8 Hz, *J*_{3'ax-2'} = 4.6 Hz, 1H, H_{3'ax}), 1.21 (s, 6H, 2 × CH₃ linker); ¹³C NMR (100 MHz, CD₃OD): δ 177.9 (CO), 175.6 (CO), 175.6 (CO), 85.3 (C₁), 75.5 (C₅), 73.9 (C₂), 73.3 (C₃), 68.9 (C₄), 63.0 (C₆), 61.1 (CH₂N₃), 52.7 (2 × OMe), 49.5 (C_{4'}), 45.2 (C_{5'}), 42.0 (C_{1'}), 41.6 (C_{2'}), 31.4 (C_{6'}), 30.5 (C_{3'}), 23.8 (CH₃ linker), 23.5 (CH₃ linker); HR-MS (ESI) calcd for C₂₁H₃₄N₄O₁₀S [M + Na]⁺ *m/z*: 557.1893; found: 557.1899.

Synthesis of the rhamnosyl aminoacid **33**

Compound **23** (58 mg, 0.093 mmol) was dissolved in CH₂Cl₂ (1.5 ml) and then TFA (0.4 ml) was added. Reaction mixture was kept stirring at RT for 1 h and then concentrated under vacuum. Residue was co-evaporated with toluene 3×. The crude was dissolved in CH₃CN (1.9 ml) and *N*-methylmorpholine (0.010 ml, 0.093 mmol), amino acid **32** (from Fluorochem, 40 mg, 0.093 mmol) and HATU (35 mg, 0.093 mmol) were added. Reaction mixture was kept stirring overnight. Then the reaction mixture was concentrated, dissolved in CHCl₃ and washed with water, sat. KHSO₄, water, sat. NaHCO₃ and water. Combined aqueous phases were additionally washed with CHCl₃ and combined organic phases were dried over Na₂SO₄ and concentrated under reduced pressure. The crude was further purified by flash chromatography (1 : 1

Hex : EtOAc) to give **33** in 92% yield (79 mg, 0.086 mmol) as colourless oil. *R*_f = 0.25 (Hex/EtOAc 1 : 1); $[\alpha]_{\text{D}}^{23}$ (CHCl₃, *c* 1.00): –37; ¹H NMR (400 MHz, CDCl₃) δ 7.76 (d, *J* = 7.4 Hz, 2H, CH-Ar-Fmoc), 7.62 (d, *J* = 7.5 Hz, 2H, CH-Ar-Fmoc), 7.45–7.35 (m, 2H, CH-Ar-Fmoc), 7.36–7.26 (m, 2H, CH-Ar-Fmoc), 6.97 (d, *J* = 6.7 Hz, 1H, NH), 5.64 (d, *J* = 8.0 Hz, 1H, NH), 5.35 (s, 2H, H₁, H₂), 5.16 (dd, *J*₃₋₄ = 10 Hz, *J*₃₋₂ = 2.9 Hz, 1H, H₃), 5.09 (dd, *J*₄₋₃ = *J*₄₋₅ = 10 Hz, 1H, H₄), 4.50–4.40 (mult., 2H, CH₂-Fmoc), 4.28–4.14 (mult., 4H, CH-Fmoc, H₅, CH-Glu, H_{4'}), 3.65 (s, 3H, COOMe), 3.63 (s, 3H, COOMe), 3.37–3.32 (m, 1H, C_{5'}), 3.07–2.96 (mult., 2H, C_{2'}, C_{1'}), 2.30–1.82 (mult., 8H, C_{3'}, C_{6'}, CH₂-Glu, CH₂-Glu), 2.12 (s, 3H, OAc), 2.06 (s, 3H, OAc), 1.98 (s, 3H, OAc), 1.47 (s, 9H, *t*Bu), 1.23 (d, *J*_{CH3-5} = 6.2 Hz, 3H, CH₃-Rha); ¹³C NMR (101 MHz, CDCl₃) δ 174.7 (CO), 174.3 (CO), 171.9 (CO), 171.2 (CO), 170.2 (CO), 170.1 (CO), 128.0 (CH-Ar-Fmoc), 127.3 (CH-Ar-Fmoc), 125.3 (CH-Ar-Fmoc), 120.2 (CH-Ar-Fmoc), 83.5 (C₁), 71.6 (C₂), 71.3 (C₄), 69.6 (C₃), 67.7 (C₅), 67.4 (CH₂-Fmoc), 53.9 (CH-Glu), 52.3 (COOMe), 52.2 (COOMe), 48.7 (C_{4'}), 47.4 (CH-Fmoc), 45.1 (C_{5'}), 40.1 (C_{1'}), 39.8 (C_{2'}), 33.0 (CH₂-Glu), 32.1 (CH₂-Glu), 29.9 (C_{3'}, C_{6'}), 28.2 (*t*Bu-3 × Me), 21.1 (OAc), 21.0 (OAc), 20.8 (OAc), 17.3 (CH₃-Rha); MS (HRMS) calcd for C₄₆H₅₈N₂O₁₆S [M + Na]⁺ *m/z*: 949.3405; found *m/z*: 949.3400.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This research was funded by the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement no. 765581 (PhD4GlycoDrug).

Notes and references

- B. Ernst and J. L. Magnani, *Nat. Rev. Drug Discovery*, 2009, **8**, 661.
- A. Tamburrini, C. Colombo and A. Bernardi, *Med. Res. Rev.*, 2020, **40**, 495–531.
- M. von Itzstein, *Nat. Rev. Drug Discovery*, 2007, **6**, 967–974.
- H. C. Kolb and B. Ernst, *Chem. – Eur. J.*, 1997, **3**, 1571–1578.
- J. Egger, C. Weckerle, B. Cutting, O. Schwardt, S. Rabbani, K. Lemme and B. Ernst, *J. Am. Chem. Soc.*, 2013, **135**, 9820–9828.
- A. Bernardi, A. Checchia, P. Brocca, S. Sonnino and F. Zuccotto, *J. Am. Chem. Soc.*, 1999, **121**, 2032–2036.
- V. Porkolab, E. Chabrol, N. Varga, S. Ordanini, I. Sutkevičiūtė, M. Thépaut, M. J. García-Jiménez, E. Girard, P. M. Nieto, A. Bernardi and F. Fieschi, *ACS Chem. Biol.*, 2018, **13**, 600–608.
- L. Medve, S. Achilli, J. Guzman-Caldentey, M. Thépaut, L. Senaldi, A. Le Roy, S. Sattin, C. Ebel, C. Vivès, S. Martin-



- Santamaria, A. Bernardi and F. Fieschi, *Chem. – Eur. J.*, 2019, **25**, 14659–14668.
- 9 D. Hauck, I. Joachim, B. Frommeyer, A. Varrot, B. Philipp, H. M. Möller, A. Imberty, T. E. Exner and A. Titz, *ACS Chem. Biol.*, 2013, **8**, 1775–1784.
- 10 R. Sommer, S. Wagner, K. Rox, A. Varrot, D. Hauck, E.-C. Wamhoff, J. Schreiber, T. Ryckmans, T. Brunner, C. Rademacher, R. W. Hartmann, M. Brönstrup, A. Imberty and A. Titz, *J. Am. Chem. Soc.*, 2018, **140**, 2537–2545.
- 11 E.-C. Wamhoff, J. Schulze, L. Bellmann, M. Rentsch, G. Bachem, F. F. Fuchsberger, J. Rademacher, M. Hermann, B. Del Frari, R. van Dalen, D. Hartmann, N. M. van Sorge, O. Seitz, P. Stoitzner and C. Rademacher, *ACS Cent. Sci.*, 2019, **5**, 808–820.
- 12 S. V. Shelke, B. Cutting, X. Jiang, H. Koliwer-Brandl, D. S. Strasser, O. Schwardt, S. Kelm and B. Ernst, *Angew. Chem., Int. Ed.*, 2010, **49**, 5721–5725.
- 13 S. Ng, N. J. Bennett, J. Schulze, N. Gao, C. Rademacher and R. Derda, *Bioorg. Med. Chem.*, 2018, **26**, 5368–5377.
- 14 L. Medve, S. Achilli, S. Serna, F. Zuccotto, N. Varga, M. Thépaut, M. Civera, C. Vivès, F. Fieschi, N. Reichardt and A. Bernardi, *Chem. – Eur. J.*, 2018, **24**, 14448–14460.
- 15 J. Schulze, H. Baukmann, R. Wawrzinek, F. F. Fuchsberger, E. Specker, J. Aretz, M. Nazaré and C. Rademacher, *ACS Chem. Biol.*, 2018, **13**, 3229–3235.
- 16 A. Brinkø, C. Risinger, A. Lambert, O. Blixt, C. Grandjean and H. H. Jensen, *Org. Lett.*, 2019, **21**, 7544–7548.
- 17 A. Tamburrini, S. Achilli, F. Vasile, S. Sattin, C. Vivès, C. Colombo, F. Fieschi and A. Bernardi, *Bioorg. Med. Chem.*, 2017, **25**, 5142–5147.
- 18 A. Tamburrini, PhD Thesis, Università degli studi di Milano, 2019.
- 19 A. Helenius and M. Aebi, *Annu. Rev. Biochem.*, 2004, **73**, 1019–1049.
- 20 C.-S. Chao, M.-C. Chen, S.-C. Lin and K.-K. T. Mong, *Carbohydr. Res.*, 2008, **343**, 957–964.
- 21 S.-J. Zhu, H.-Z. Ying, Y. Wu, N. Qiu, T. Liu, B. Yang, X.-W. Dong and Y.-Z. Hu, *RSC Adv.*, 2015, **5**, 103172–103183.
- 22 G. Yang, R. W. Franck, R. Bittman, P. Samadder and G. Arthur, *Org. Lett.*, 2001, **3**, 197–200.
- 23 S. Mari, H. Posterl, G. Marcou, D. Potenza, F. Micheli, F. J. Cañada, J. Jimenez-Barbero and A. Bernardi, *Eur. J. Org. Chem.*, 2004, 5119–5225.
- 24 J. L. Jat, M. P. Paudyal, H. Gao, Q.-L. Xu, M. Yousufuddin, D. Devarajan, D. H. Ess, L. Kürti and J. R. Falck, *Science*, 2014, **343**, 61–65.
- 25 A. Mordini, F. Russo, M. Valacchi, L. Zani, A. Degl'Innocenti and G. Reginato, *Tetrahedron*, 2002, **58**, 7153–7163.
- 26 M. Punk, C. Merkley, K. Kennedy and J. B. Morgan, *ACS Catal.*, 2016, **6**, 4694–4698.
- 27 T. Mita and E. N. Jacobsen, *Synlett*, 2009, 1680–1684.
- 28 M. Senatore, A. Lattanzi, S. Santoro, C. Santi and G. D. Sala, *Org. Biomol. Chem.*, 2011, **9**, 6205–6207.
- 29 A. Bernardi, D. Arosio, L. Manzoni, F. Micheli, A. Pasquarello and P. Seneci, *J. Org. Chem.*, 2001, **66**, 6209–6216.
- 30 J. Jiang, M. Artola, T. J. M. Beenakker, S. P. Schröder, R. Petracca, C. de Boer, J. M. F. G. Aerts, G. A. van der Marel, J. D. C. Codée and H. S. Overkleeft, *Eur. J. Org. Chem.*, 2016, 3671–3678.
- 31 P. Serrano, A. Llebaria, J. Vázquez, J. de Pablo, J. M. Anglada and A. Delgado, *Chem. – Eur. J.*, 2005, **11**, 4465–4472.
- 32 T. Belz and S. J. Williams, *Carbohydr. Res.*, 2016, **429**, 38–47.
- 33 A. Ané, S. Josse, S. Naud, V. Lacône, S. Vidot, A. Fournial, A. Kar, M. Pipelier and D. Dubreuil, *Tetrahedron*, 2006, **62**, 4784–4794.
- 34 H. Hashimoto, K. Shimada and S. Horito, *Tetrahedron: Asymmetry*, 1994, **5**, 2351–2366.
- 35 P. Shu, J. Zeng, J. Tao, Y. Zhao, G. Yao and Q. Wan, *Green Chem.*, 2015, **17**, 2545–2551.
- 36 G. R. Morais, I. F. Oliveira, A. J. Humphrey and R. A. Falconer, *Carbohydr. Res.*, 2010, **345**, 160–162.
- 37 U. Dabrowski, H. Friebolin, R. Brossmer and M. Supp, *Tetrahedron Lett.*, 1979, **20**, 4637–4640.
- 38 H. Hori, T. Nakajima, Y. Nishida, H. Ohruai and H. Meguro, *Tetrahedron Lett.*, 1988, **29**, 6317–6320.
- 39 L. Deng, X. Wang, S. Uppalapati, O. Norberg, H. Dong, A. Joliton, M. Yan and O. Ramström, *Pure Appl. Chem.*, 2013, **85**, 1789–1801.
- 40 R. Caraballo, L. Deng, L. Amorim, T. Brinck and O. Ramström, *J. Org. Chem.*, 2010, **75**, 6115–6121.
- 41 S. Josse, J. Le Gal, M. Pipelier, J. Cléophax, A. Olesker, J.-P. Pradère and D. Dubreuil, *Tetrahedron Lett.*, 2002, **43**, 237–239.
- 42 M. Adinolfi, D. Capasso, S. Di Gaetano, A. Iadonisi, L. Leone and A. Pastore, *Org. Biomol. Chem.*, 2011, **9**, 6278–6283.
- 43 L. M. Doyle, S. O'Sullivan, C. Di Salvo, M. McKinney, P. McArdle and P. V. Murphy, *Org. Lett.*, 2017, **19**, 5802–5805.
- 44 W. Pilgrim and P. V. Murphy, *J. Org. Chem.*, 2010, **75**, 6747–6755.
- 45 E. Juaristi and G. Cuevas, *Tetrahedron*, 1992, **48**, 5019–5087.
- 46 R. T. C. Sheridan, J. Hudon, J. A. Hank, P. M. Sondel and L. L. Kiessling, *ChemBioChem*, 2014, **15**, 1393–1398.
- 47 P. Karmakar, K. Lee, S. Sarkar, K. A. Wall and S. J. Sucheck, *Bioconjugate Chem.*, 2016, **27**, 110–120.
- 48 M. Herczeg, E. Mező, N. Molnár, S.-K. Ng, Y.-C. Lee, M. Dah-Tsyr Chang and A. Borbás, *Chem. – Asian J.*, 2016, **11**, 3398–3413.
- 49 M. K. Hossain, A. Vartak, P. Karmakar, S. J. Sucheck and K. A. Wall, *ACS Chem. Biol.*, 2018, **13**, 2130–2142.
- 50 B. Liet, E. Laigre, D. Goyard, B. Todaro, C. Tiertant, D. Boturyn, N. Berthet and O. Renaudet, *Chem. – Eur. J.*, 2019, **25**, 15508–15515.
- 51 J. Alsarraf, P. Gormand, J. Legault, M. Mihoub and A. Pichette, *Tetrahedron Lett.*, 2020, **61**, 151706.
- 52 A. Bernardi and S. Sattin, *Eur. J. Org. Chem.*, 2020, 4652–4663.

